Vicore Pharma AB

🏆 Vicore Pharma Receives the 2024 SwedenBIO Award! 🏆 We are honored to be recognized with the 2024 SwedenBIO Award, celebrating Vicore's many achievements this year. 2024 has been a transformative year, with milestones that reflect our unwavering commitment to innovation and improving patient outcomes: ✨ Presenting a Phase 2a dataset for buloxibutid in idiopathic pulmonary fibrosis (#IPF), showcasing unprecedented efficacy in treating this devastating disease. ✨ Entering into a strategic partnership to advance the development of buloxibutid in Japan. ✨ Receiving Breakthrough Designation from the FDA for our groundbreaking digital therapy. ✨ Securing an $85 million financing, anchored by top-tier investors, to support our Phase 2b IPF study—which is now successfully underway. Thank you to SwedenBIO for this honor and for believing in Vicore's vision. Here's to continued progress in 2025 and beyond! #VicorePharma #SwedenBIOAward #Innovation #IPF

Vicore is happy to announce publication of the COMPANION study on our digital therapy Almee for people with PF. Link below in the journal Respirology. Many thanks to all involved. https://lnkd.in/dJv5a_m6 Asian Pacific Society of Respirology PF Warriors Pulmonary Fibrosis Foundation Breathe Support Network Wescoe Foundation for Pulmonary Fibrosis Alex Therapeutics

We are excited to announce that Vicore is one of three finalists to the SwedenBIO award in good company with Pelago Bioscience AB and Xbrane Biopharma AB. We are looking forward to attending the SwedenBIO Summit in Stockholm on December 11 where the announcement of the winner will take place. https://lnkd.in/dAKuHYgp

We are thrilled to announce our sponsorship and participation in the Pulmonary Fibrosis Foundation’s (#PFF) Education Symposium this week. Vicore will be presenting on our ASPIRE IPF trial as part of the Clinical Trial Innovation Series. Don't miss this chance to learn more about our work and the latest advancements in pulmonary fibrosis treatment! 📅 Date: Friday, November 8th 🕛 Time: 12:00 PM CST 🎤 Session: Clinical Trial Innovation Series Join us as we work together to drive awareness, support patients, and foster innovation in the field! #PulmonaryFibrosis #PFF #HealthcareInnovation #PulmonaryResearch

We are thrilled to announce the initiation of the global, randomized Phase 2b ASPIRE trial, a pivotal step forward in our ongoing efforts to develop innovative treatments for idiopathic pulmonary fibrosis (#IPF). It is especially fitting that we are launching this important trial during Pulmonary Fibrosis Awareness Month, highlighting our dedication to raising awareness and finding solutions for these debilitating diseases. Our collaboration with PSI CRO AG is central to this undertaking, bringing together our shared expertise and commitment to making a difference in the lives of patients affected by IPF. You can find more information on the trial here: https://lnkd.in/e47PThKP #PFMonth #PulmonaryFibrosisAwarenessMonth #BlueUp4PF #clincialresearch #buloxibutid #Vicore

This week, members of the Vicore team presented exciting new data at the European Respiratory Society Annual World Congress 2024 in Vienna. Vicore’s presentations further describe the power of buloxibutid’s upstream tissue-repair mechanism and highlight the patient-friendly design of the Phase 2b ASPIRE trial investigating buloxibutid in #IPF.  Check out the e-posters available on our website! https://lnkd.in/exKB4KG3    #ERS #EuropeanRespiratorySociety #buloxibutid #Vicore

An exciting week at the 8th Annual IPF Summit has come to an end, it has been a week of great interactions and learnings. Vicore CMO Professor Bertil E. Lindmark MD, PhD did a presentation on clinical development within #IPF, the importance of reducing fibrosis and promoting alveolar healing to increase of lung function, as seen in our phase 2a AIR trial. #IPFsummit #Vicore #buloxibutid

Looking to make a difference in the lives of patients with #ipf? Come join our dynamic team at Vicore and be a part of this exciting new stage of growth! We are currently looking to hire Clinical Science Liaisons (#CSLs) in the US and Europe. Read more about these opportunities and apply here: US: https://lnkd.in/d69CWmcn UK: https://lnkd.in/dqd52Sxr Germany/Austria: https://lnkd.in/d86Gm5XS #TeamVicore #hiring

Come join our fantastic team! We are looking for a QA Manager GMP to our office in Hørsholm, Denmark. Read more about the position and apply here: https://lnkd.in/d2FnpeTf

Vicore Pharma AB is pleased to announce positive final results from the Phase 2a AIR trial demonstrating that buloxibutid improves lung function over 36 weeks in patients with idiopathic pulmonary fibrosis (#IPF). These encouraging results were presented yesterday by Toby Maher, Keck School of Medicine of USC, as a late-breaking oral session at the American Thoracic Society International Congress (#ATS2024). Vicore will be discussing the results in more detail during a webinar on Wednesday 5/22 at 10:00 ET/16:00 CET. You can register for the webinar here: https://lnkd.in/eKp8xYGj #pulmonaryfibrosis #biotechnews #respiratory #clinicaldata